{"id":140474,"title":"Archived 19: Summary of National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following a 1- or 2-dose primary series - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2025-04-18","captureTimestamp":"2025-04-18T14:14:28.028000+00:00","jobId":1,"originalUrl":"https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html?wbdisable=true","snippet":"Archived 19: Summary of National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following a 1- or 2-dose primary series - Canada.ca Skip to main content Skip to \"About government\" We have archived…","rawSnapshotUrl":"/api/snapshots/raw/140474","browseUrl":"https://replay.healtharchive.ca/job-1/20250418141428/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/summary-september-10-2021-additional-dose-covid-19-vaccine-immunocompromised-following-1-2-dose-series.html?wbdisable=true#ha_snapshot=140474","mimeType":"text/html","statusCode":200}